Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVL006 + trastuzumab deruxtecan
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CVL006 + trastuzumab deruxtecan is an investigational **combination therapy** currently under clinical development for the treatment of **advanced solid tumors** including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, and other tumor types. CVL006 is an immunoglobulin G1 (IgG1) monoclonal antibody targeting a checkpoint pathway (precise molecular target not fully public), while trastuzumab deruxtecan (also known as DS-8201a, T-DXd, Enhertu) is an **antibody-drug conjugate (ADC)** comprising a HER2-targeted antibody linked to a topoisomerase I inhibitor payload. The combination aims to leverage the immunomodulatory effects of CVL006 with the targeted cytotoxicity of trastuzumab deruxtecan for synergistic antitumor activity. The regimen is administered intravenously and is currently being evaluated in phase I/II trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in multiple advanced solid tumor indications, including HER2-positive and HER2-low tumors[1][3].
- Other names
- trastuzumab deruxtecanCVL006 + DS-8201a
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CVL006 + trastuzumab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVL006 + trastuzumab deruxtecan.